Pfizer’s Mylotarg is back on the US market after a ... acute myeloid leukaemia patients whose tumours express the CD33 antigen, and adults and children two years and older with relapsed or ...

The committee voted 6-1 that Mylotarg in combination with chemotherapy has a favourable risk-benefit profile for patients with newly-diagnosed CD33-positive AML. The FDA is not bound to follow its ...

in which healthy transplant donor cells are genetically engineered by removing CD33, with the potential to enable targeted therapies such as Mylotarg and CD33-targeted CAR-T therapy post ...